Sistemic announces companion biomarker programme

Published: 4-Jul-2011
Research & Development

Extends miRNA drug discovery toolkit

Sistemic, a global company with expertise in microRNA, has released a new companion biomarker programme, which extends its SistemRNA suite of drug discovery and development tools.

The firm, based in Glasgow in Scotland and Boston, US, says this programme simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research. The new multiple miRNA biomarkers can be used to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

Companion biomarkers are the most recent extension of microRNA technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.

The firm says the system will use miRNA to identify highly discriminatory biomarkers, which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.

See more

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Read more
Cell therapy companies to be offered a streamlined process for clinical trials

Trending Articles

  1. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  2. NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
  3. Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
  4. AstraZeneca's tozorakimab succeeds in third pivotal Phase III COPD trial The positive results have shown that tozorakimab significantly reduced moderate-to-severe COPD exacerbations, adding to the earlier positive results from the OBERON and TITANIA trials and further supporting its potential as a first-in-class IL-33-targeting biologic
  5. Cleanroom Technology Awards 2026: The winners The winners of the Cleanroom Technology Awards 2026 have now been revealed. The 2026 edition brought together some of the most forward-thinking organisations in the industry, recognising innovation, technical excellence, and impactful advancements across cleanroom design, operation, and technology

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development

NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing

The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development

Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme

The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Manufacturing

Precision meets innovation in melting point determination

Advancing analytical accuracy with automated thermal analysis
Subscribe now